Pathology Slide Quality Control AI Market Report 2026

The pathology slide quality control artificial intelligence market size has grown exponentially in recent years. It will grow from $0.53 billion in 2025 to $0.64 billion in 2026 at a compound annual growth rate (CAGR) of 21.3%. The growth in the historic period can be attributed to increasing adoption of digital pathology, growing need for accurate diagnostics, rising demand for workflow automation, expansion of laboratory infrastructure, and increasing focus on quality assurance.

The pathology slide quality control artificial intelligence market size is expected to see exponential growth in the next few years. It will grow to $1.38 billion in 2030 at a compound annual growth rate (CAGR) of 21%. The growth in the forecast period can be attributed to growing integration of artificial intelligence in pathology, rising investments in artificial intelligence (AI)-based quality control, increasing regulatory support for digital pathology, expansion of cloud-based pathology platforms, and growing adoption of telepathology solutions. Major trends in the forecast period include technology advancements in slide scanning, innovations in artificial intelligence (AI)-based image analysis, developments in automated tissue quality assessment, research and developments in artifact detection, and advancements in stain and section quality evaluation.

The rising volume of diagnostic testing is expected to drive the growth of the pathology slide quality control artificial intelligence (AI) market in the coming years. Increasing diagnostic volumes refer to the growing number of medical tests and tissue analyses conducted to detect diseases, fueled by aging populations and expanded screening programs. Advancements in digital pathology support the management of these growing volumes, as automated tools are required to maintain accuracy and efficiency in high-throughput environments. Pathology slide quality control AI enhances diagnostic workflows by using machine learning algorithms to automatically detect errors, artifacts, and anomalies in digital slide images before pathologist review. For example, according to NHS England, the UK-based publicly funded healthcare system, an average of 2.4 million diagnostic tests were conducted per month during 2024/25, marking an 8% increase from the previous year. Consequently, the expansion of diagnostic testing volumes is propelling the growth of the pathology slide quality control AI market.

Major companies in the pathology slide quality control artificial intelligence (AI) market are focusing on technological advancements, such as introducing AI-powered automated quality control solutions integrated into digital pathology workflows. These solutions use deep learning algorithms to automatically detect and flag artifacts, out-of-focus areas, and other quality issues in whole-slide images before pathologist review, reducing manual workload, minimizing diagnostic errors, and ensuring high-quality inputs for subsequent analysis. For example, in March 2023, Aiosyn B.V., a Netherlands-based medical software company specializing in AI-powered pathology solutions, launched AiosynQC, an AI-driven automated quality control platform. This modular software integrates with existing digital pathology systems to identify and highlight out-of-focus regions and other artifacts in hematoxylin and eosin (H&E) stained slide images, supporting a more efficient and accurate quality review process for research and diagnostic laboratories.

In August 2025, Tempus AI Inc., a US-based technology company specializing in artificial intelligence for precision medicine, acquired Paige for approximately $81.25 million. Through this acquisition, Tempus AI Inc. aimed to expand its digital pathology portfolio and reinforce its position in AI-driven precision medicine by incorporating Paige's extensive dataset of millions of digitized pathology slides and advanced AI applications into its multimodal data library. Paige is a US-based AI company focused on digital pathology solutions and clinical AI applications for cancer diagnosis and treatment planning.

Major companies operating in the pathology slide quality control artificial intelligence (AI) market are F. Hoffmann-La Roche Ltd., Philips Healthcare, Leica Biosystems GmbH, XIFIN Inc., Stratipath Inc., PathAI Inc., Owkin Inc., Lunit Inc., Paige.AI Inc., Proscia Inc., Visiopharm A/S, Indica Labs Inc., Inspirata Inc., PreciseDx Inc., Aiforia Technologies Oyj, Ibex Medical Analytics Ltd., Deep Bio Inc., Nucleai Ltd., AIRA Matrix Inc., HistoIndex Pte Ltd., Techcyte Inc.

North America was the largest region in the pathology slide quality control artificial intelligence market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pathology slide quality control artificial intelligence (AI) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pathology slide quality control artificial intelligence (AI) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are impacting the pathology slide quality control artificial intelligence market by increasing costs of imported digital slide scanners, high-performance computing hardware, imaging sensors, and data storage systems required for ai-driven pathology workflows. hospitals and diagnostic laboratories in north america and europe are most affected due to reliance on advanced imported hardware, while asia-pacific faces cost pressures on scanner manufacturing and deployment. these tariffs are increasing upfront capital expenditure and slowing procurement cycles for smaller laboratories. however, they are also encouraging localized hardware assembly, regional software development, and greater adoption of cloud-based quality control solutions that reduce dependency on imported infrastructure.

Pathology slide quality control artificial intelligence refers to software systems that leverage advanced algorithms and machine learning techniques to automatically assess digital pathology slides for issues such as focus errors, staining variability, artifacts, and tissue coverage prior to diagnostic review. These systems are used to maintain consistent slide quality, reduce manual review workload, prevent diagnostic delays, and enhance accuracy and efficiency in pathology workflows.

The primary components of pathology slide quality control artificial intelligence (AI) include software, hardware, and services. Software refers to AI-driven platforms designed to automate evaluation of pathology slides, detect errors, and ensure consistent quality across pre-analytic, analytic, and post-analytic processes. Different deployment modes include on-premises and cloud-based. Multiple applications cover quality assurance tools (dedicated quality control), pre-analytic quality control, analytic quality control, post-analytic quality control, and workflow management, and they are used by several end users comprising hospitals, diagnostic laboratories, research institutes, academic centers, and others.

The pathology slide quality control artificial intelligence market consists of revenues earned by entities by providing services such as automated slide quality assessment, focus and blur detection, staining consistency evaluation, artifact identification, and pre-diagnostic slide validation. The market value includes the value of related goods sold by the service provider or included within the service offering. The pathology slide quality control artificial intelligence market also includes sales of artificial intelligence-powered quality control software, digital pathology analysis platforms, slide assessment algorithms, workflow integration tools, and quality reporting modules. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.